About Us
A brief profile of companyCompany Overview
Company Status
• Company Name : CELLASTER, Inc.
• CEO : Dr. JANG HO-YEON & Dr. JEON SEONG-HA
• Date of Establishment : 08, Nov. 2018
• Company Capital : More than US$ 1 Million
• Business Area : Pharmaceutical & BIO-IT/Medical-IT/Healthcare-IT CMO/CDMO/CMC(under feasibility study)
• H.Q. Address : #415, GTX-Central Bldg, 22, Harmony-ro, 178beon-gil,
Yeonsu-gu, Incheon, 22011, Rep. of Korea
• Tel. : +82-32-831-3825 • Fax. : +82-32-833-3825
• E-Mail : info@cellaster.com
Company History
Key Persons
Core Members
• Doctor of Engineering (Ph.D.)
• Major in Computer Science
• KAIST(Korea Advanced Institute of Science and Technology)
• Seoul Venture Univ.
• Doctor of Science (Ph.D.)
• Major in Biochemistry, Immunology and Neuroscience
• Imperial College London
• King’s College London
• Manchester Univ. in England
• Major in Business Administration
• Graduated from Hongik Univ.
• V.P / Marketing
• Doctor of Medicine (M.D.)
• Busan National Univ. School of Medicine
• Ophthalmologist
• Adjunct Prof. at Busan Baik Hospital
• Chief Doctor of Busan Lee-Young Eye Clinic.
• Master of Science
• Major in Biochemistry
• Kyungpook National University
• Various experiences over 20 years
in Pharmaceutical Development
• Pharmaceuticals Development / Director
Advisory Group
For Pharmaceuticals
• M.D. & Ph.D.
• Professor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• Tumor Biologist
• Inventor of CAP-1 related patents
Education/Training
| INSTITUTION AND LOCATION | DEGREE (if applicable) |
YEAR(s) | FIELD OF STUDY |
| Yonsei University, Seoul, KOREA | M.D. | 1995 | Medicine |
| Yonsei University, Seoul, KOREA | Ph.D. | 2006 | Tumor Biology |
| UT MD Anderson Cancer Center, Houston, Tx, U.S.A | Postdoc | 2006~2009 | Molecular Therapeutics and Systems Biology |
Position/Employment
• 1996-2000 Residency, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA• 2003-2005 Clinical and research fellow, Division of Gastric Cancer Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• 2005 Instructor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• 2006- Postdoctoral fellow, Department of Molecular Therapeutics and GI medical Oncology, UT MD Anderson Cancer Center
• 2007- 2009 Odyssey Fellow, Department of Systems Biology, Kleberg Center for Molecular Markers, UT MD Anderson Cancer Center
• 2006- Assistant Professor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• 2012- Associate Professor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• 2012- 2016 Vice Director, Office of Medical Science Research Affairs/Industry-Academy Cooperation Foundation, Yonsei University Health System, Seoul, Korea
• 2017- Vice Dean, Research Affairs, Yonsei University College of Medicine, Seoul, Korea
• 2017- Professor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
• 2019- Director, Institute for Precision Cancer Therapy, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KOREA
• 2020- Director General, Biocluster Core Strategy Agency, Yonsei University Health System
Honors
• 2004 6th GSK Oncology Academic Award, Korea Cancer Association• 2004 2nd Cancer Academic Award, Korean Gastric Cancer Association
• 2005 Best article of the year Department of Surgery, Yonsei Univ. College of Medicine
• 2007 Odyssey Fellowship award Theodore N. Law Scientific Achievement MD Anderson Cancer Center, Houston
• 2012 Cancer Academic Award, Basic cancer research, Korean Gastric Cancer Association
• 2013 18th Sanofi-Aventis Award for Research Excellence, Korean Gastric Cancer Association
• 2018 Industry-Academia Collaboration Excellence Award Yonsei University College of Medicine
• 2019 Cancer Research Excellence Award, Korean Gastric Cancer Association
• 2019 32th Bowon Academic Award, Yonsei University College of Medicine
• 2019 52th Yuhan Medical Award, Grand Prize, Seoul Medical Association
• 2019 13th Doosan Yonkang Surgical Academic Award, Doosan Yonkang Foundation, Korean Surgical Society
• 2019 18th The President’s Commendation for Distinct Service to the State, Ministry of Health & Welfare. KOREA
• 2020 2nd Yeom-Gok Academic Award, Yonsei University College of Medicine
Publications
Selected Recent Publications (last 4 years out of 178 SCI publications)1. Jae-Ho Cheong*, Sam C Wang, Sunho Park, Matthew R Porembka, Alana L Christie, Hyunki Kim, Hyo Song Kim, Hong Zhu, Woo Jin Hyung, Sung Hoon Noh, Bo Hu, Changjin Hong, John D Karalis, In-Ho Kim, Sung Hak Lee, Tae Hyun Hwang*. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer Nature Commun (IF:14.9191) 2022;13:774
2. Ji-Yong Sung, Jae-Ho Cheong* Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer Cancer Commune (IF:10.39) 2022
3. Minjeong Jang†, Jinhyeon An, Seung Won Oh, Joo Yeon Lim, Joon Kim, Jung Kyoon Choi*, Jae-Ho Cheong*, Pilnam Kim*. Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer Nature Biomedical Engineering (IF:25.67) 2021
4. Ji-Yong Sung and Jae-Ho Cheong. Alternative lengthening of telomeres is mechanistically linked to potential therapeutic vulnerability in the stem-like subtype of gastric cancer Clinical and Transl Med (IF:11.5) 2021
5. Hae-Ji Choi, Yoo-Lim Jhe, Jungmin Kim, Ju Yeon Lim, Jae Eun Lee, Min-Kyue Shin,Jae-Ho Cheong*. FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells Redox Biol (IF:11.8) 2020:36:101589
6. Jeong MH, Park SY, Lee SH, Seo J, Yoo JY, Park SH, Kim MJ, Lee S, Jang S, Choi HK, Lee JE, Shin SJ, Choi KC, Cheong JH*, Yoon HG*. EPB41L5 mediates TGF-beta-induced metastasis of gastric cancer Clin Cancer Res (IF:10.2) 2019 Jun 15;25(12):3617-3629
7. Cheong JH*, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, Gu MJ, Kim HY, Lee J, Choi SH, Hong S, Kim JW, Choi YY, Hyung WJ, Jang E, Kim H, Huh YM, Noh SH. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis Lancet Oncol (IF:36.4) 2018 May;19(5):629-638
8. Oh SC*, Sohn BH*, Cheong JH*, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype Nature Commun (IF:12.4) 2018 May 3;9(1):1777
9. Lee J, Kim H, Lee JE, Shin S-J, Oh J, Kwon S, Kim H, Choi YY, White M, Paik S, Cheong JH* and Kim H*. Selective cytotoxicity of the NAMPT inhibitor FK855 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT Gastroenterology (IF:20.8) 2018;155:798-814.
10. Park KC, Kim SW, Jeon JY, Jo AR, Choi HJ, Kim J, Lee HG, Kim Y, Mills G, Noh SH, Lee MG, Park ES, and Cheong JH*. Survival of cancer stem-like cells under metabolic stress via CaMK2alpha-mediated upregulation of sarco/endoplasmic reticulum calcium ATPase expression Clin Cancer Res (IF:10.2), 2018 Apr 1;24(7):1677-1690.
11. Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, Gu MJ, Choi SH, Hong S, Kim JW, Hyung WJ, Noh SH, Cheong JH*. Microsatellite instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study Ann Surg (IF:9.2). 2019 Aug;270(2):309-316
• Doctor of Science (Ph.D.)
• Molecular Biologist
• Professor, Yonsei University School of Medicine, Seoul, Korea
• Inventor of CAP-1 related patents
Dr. Yoon is a molecular biologist specializing in epigenetics, cancer biology, and fibrotic diseases. He has a laboratory at Avison Biomedical Research Center, Yonsei University School of Medicine, which has state-of-the-art research facilities and the largest animal lab in Korea, and has recently focused on developing targeted therapeutics for intractable & chronic diseases such as cancer and fibrotic diseases (IPF, NASH, CKD). To this end, he published a number of intellectual property rights and international academic journals, and transferred a number of technologies to Bio-companies. Furthermore, he is focusing on the development of therapeutic antibodies and compounds with the goal of developing targeted therapeutics for intractable tissue fibrosis diseases in the future.
• Doctor of Science (Ph.D.)
• Biochemist and Molecular Biologist
• Professor, Ulsan College of Medicine,
Asan Medical Center (AMC) in Korea
• Inventor of CAP-1 related patents
Dr. Choi is a Professor at the Department of Biomedical Sciences, and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea. He received his BS degree and MS degree at Korea University, and received Ph.D. degree in Department of Biochemistry and Molecular Biology at Yonsei University College of Medicine in 2010. He developed his carrier when he worked as a postdoctoral training at the Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine. Currently, he is a Professor at the University of Ulsan College of Medicine, Asan Medical Center (AMC) in Korea from 2011. His main focus of research is on the epigenetic regulation of cancer development and metastasis, and on the molecular mechanism of epigenetic regulators in cancer (GBM, Breast cancer, Pancreatic cancer, etc) and inflammation. Also, his research has focused on the discovery of novel epigenetic inhibitors, the development of humanized antibodies, and the screening of small compounds for the therapy of cancer cells and cancer stem cells.
Working with
Business Area
